Aldeyra Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Aldeyra Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.85M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($55.85M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($37.54M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($62.02M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($57.78M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($37.55M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($60.83M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($38.89M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($22.34M) | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($18.70M) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($35.27M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($60.12M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($42.79M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($62.68M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($56.22M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($36.42M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($63.07M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($39.70M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($22.49M) | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($18.70M) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.66M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $48.22M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $29.46M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $47.31M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $44.94M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $24.68M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $44.35M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $29.82M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $16.30M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $13.18M | Mar 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.35M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($43.21M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($30.33M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($56.64M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($42.56M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($37.49M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($44.98M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($29.86M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($19.22M) | Mar 8, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Mar 7, 2024 |
| FY2023 | Dec 31, 2022 | $16.3K | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $7.8K | Mar 9, 2023 |
| FY2020 | Dec 31, 2019 | $9.5K | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $263.0K | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $24.8K | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $11.8K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $86.1K | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $14.1K | Mar 30, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.06M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $104.61M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $148.33M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $181.29M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $233.14M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $83.35M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $75.52M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $95.09M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $44.17M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $25.19M | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.81M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $33.60M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $28.53M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $30.28M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $27.40M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $23.84M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $27.44M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $8.47M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $4.57M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $3.54M | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.25M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $71.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $119.80M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $151.01M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $205.74M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $59.51M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $48.08M | Mar 17, 2022 |
| FY2020 | Dec 31, 2018 | $86.62M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $39.60M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $21.65M | Mar 8, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($483.96M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($450.11M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($394.26M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($356.72M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($294.69M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($236.92M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($199.36M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($138.54M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($99.64M) | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($77.30M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.04M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $54.53M | Feb 27, 2026 |
| FY2023 | Dec 31, 2022 | $144.42M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $229.79M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $77.86M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $44.43M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $47.36M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $20.02M | Mar 8, 2019 |
| FY2018 | Dec 31, 2016 | $12.02M | Mar 8, 2019 |
| FY2017 | Jan 1, 2016 | $14.65M | Mar 29, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.30M | Feb 27, 2026 |
| FY2024 | Dec 31, 2024 | $15.30M | Feb 28, 2025 |
| FY2023 | Dec 31, 2023 | $15.29M | Mar 7, 2024 |
| FY2022 | Dec 31, 2022 | $16.34M | Mar 9, 2023 |
| FY2021 | Dec 31, 2021 | $16.04M | Mar 17, 2022 |
| FY2020 | Dec 31, 2020 | $16.04M | Mar 11, 2021 |
| FY2019 | Dec 31, 2019 | $16.04M | Mar 12, 2020 |
| FY2017 | Dec 31, 2017 | $1.40M | Mar 29, 2018 |
| FY2016 | Dec 31, 2016 | $1.40M | Mar 30, 2017 |
| FY2015 | Dec 31, 2015 | $1.40M | Mar 30, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 9, 2023 |
| FY2015 | Dec 31, 2015 | (1) | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | (2) | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | 3 | Mar 23, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 9, 2023 |
| FY2015 | Dec 31, 2015 | (1) | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | (3) | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | (17) | Mar 23, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 60.16M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 59.65M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 59.20M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 58.56M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 58.08M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 38.67M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | 28.66M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 26.24M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 19.14M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | 12.58M | Mar 29, 2018 |